메뉴 건너뛰기




Volumn 12, Issue 6, 2011, Pages 839-843

Modern treatment of patients at risk: Still a HOPE for ACE inhibitors?

Author keywords

ACE inhibitors; coronary artery disease; heart failure; meta analysis; secondary prevention

Indexed keywords

ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PERINDOPRIL; PLACEBO; QUINAPRIL; RAMIPRIL; TRANDOLAPRIL;

EID: 79952773856     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2011.546348     Document Type: Review
Times cited : (5)

References (20)
  • 2
    • 46049090018 scopus 로고    scopus 로고
    • The primary and secondary prevention of coronary artery disease: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition)
    • DOI 10.1378/chest.08-0685
    • Becker RC, Meade TW, Berger PB, et al. The primary and secondary prevention of coronary artery disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. 8th edition. Chest 2008;133:776S-814S (Pubitemid 351894917)
    • (2008) Chest , vol.133 , Issue.6 SUPPL. 6
    • Becker, R.C.1    Meade, T.W.2    Berger, P.B.3    Ezekowitz, M.4    O'Connor, C.M.5    Vorchheimer, D.A.6    Guyatt, G.H.7    Mark, D.B.8    Harrington, R.A.9
  • 3
    • 0010838455 scopus 로고    scopus 로고
    • Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: A systematic overview of data from individual patients
    • Flather MD, Yusuf S, Kober L, et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet 2000;355:1575-81 (Pubitemid 30240501)
    • (2000) Lancet , vol.355 , Issue.9215 , pp. 1575-1581
    • Flather, M.D.1    Yusuf, S.2    Kober, L.3    Pfeffer, M.4    Hall, A.5    Murray, G.6    Torp-Pedersen, C.7    Ball, S.8    Pogue, J.9    Moye, L.10    Braunwald, E.11
  • 4
    • 33645740812 scopus 로고    scopus 로고
    • Angiotensin-converting enzyme inhibitors in patients with coronary artery disease and absence of heart failure or left ventricular systolic dysfunction: An overview of long-term randomized controlled trials
    • Danchin N, Cucherat M, Thuillez C, et al. Angiotensin-converting enzyme inhibitors in patients with coronary artery disease and absence of heart failure or left ventricular systolic dysfunction: an overview of long-term randomized controlled trials. Arch Intern Med 2006;166:787-96
    • (2006) Arch Intern Med , vol.166 , pp. 787-96
    • Danchin, N.1    Cucherat, M.2    Thuillez, C.3
  • 5
    • 79952773487 scopus 로고    scopus 로고
    • Imagine how many lives you save: Angiotensin converting enzyme inhibition for vascular atherosclerosis in the present era of risk reduction
    • Ennezat PV, Vannesson C, Bouabdallaoui N, et al. Imagine how many lives you save: angiotensin converting enzyme inhibition for vascular atherosclerosis in the present era of risk reduction. Expert Opin Pharmacother 2011;12(6):883-9
    • (2011) Expert Opin Pharmacother , vol.12 , Issue.6 , pp. 883-9
    • Ennezat, P.V.1    Vannesson, C.2    Bouabdallaoui, N.3
  • 6
    • 0034688194 scopus 로고    scopus 로고
    • Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients
    • DOI 10.1056/NEJM200001203420301
    • Yusuf S, Sleight P, Pogue J, et al.; The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145-53 (Pubitemid 30051645)
    • (2000) New England Journal of Medicine , vol.342 , Issue.3 , pp. 145-153
    • Yusuf, S.1
  • 7
    • 0033860871 scopus 로고    scopus 로고
    • Randomized, placebo-controlled trial of the angiotensin-converting enzyme inhibitor, ramipril, in patients with coronary or other occlusive arterial disease
    • DOI 10.1016/S0735-1097(00)00736-1, PII S0735109700007361
    • MacMahon S, Sharpe N, Gamble G, et al. Randomized, placebo-controlled trial of the angiotensin-converting enzyme inhibitor, ramipril, in patients with coronary or other occlusive arterial disease. PART-2 Collaborative Research Group. Prevention of atherosclerosis with ramipril. J Am Coll Cardiol 2000;36:438-43 (Pubitemid 30624005)
    • (2000) Journal of the American College of Cardiology , vol.36 , Issue.2 , pp. 438-443
    • MacMahon, S.1    Sharpe, N.2    Gamble, G.3    Clague, A.4    Ni Mhurchu, C.5    Clark, T.6    Hart, H.7    Scott, J.8    White, H.9
  • 8
    • 0035968623 scopus 로고    scopus 로고
    • Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack
    • PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001;358:1033-41
    • (2001) Lancet , vol.358 , pp. 1033-41
  • 9
    • 0026786643 scopus 로고
    • Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial
    • The SAVE Investigators
    • Pfeffer MA, Braunwald E, Moye LA, et al.; The SAVE Investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. N Engl J Med 1992;327:669-77
    • (1992) N Engl J Med , vol.327 , pp. 669-77
    • Pfeffer, M.A.1    Braunwald, E.2    Moye, L.A.3
  • 10
    • 0025913812 scopus 로고
    • Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure
    • The SOLVD Investigators
    • The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302
    • (1991) N Engl J Med , vol.325 , pp. 293-302
  • 11
    • 0026785561 scopus 로고
    • Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions
    • The SOLVD Investigattors
    • The SOLVD Investigattors. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992;327:685-91
    • (1992) N Engl J Med , vol.327 , pp. 685-91
  • 12
    • 0042330455 scopus 로고    scopus 로고
    • Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: Randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study)
    • DOI 10.1016/S0140-6736(03)14286-9
    • Fox KM. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003;362:782-8 (Pubitemid 37093919)
    • (2003) Lancet , vol.362 , Issue.9386 , pp. 782-788
    • Fox, K.M.1
  • 13
    • 19644400972 scopus 로고    scopus 로고
    • Angiotensin-converting-enzyme inhibition in stable coronary artery disease
    • Braunwald E, Domanski MJ, Fowler SE, et al. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 2004;351:2058-68
    • (2004) N Engl J Med , vol.351 , pp. 2058-68
    • Braunwald, E.1    Domanski, M.J.2    Fowler, S.E.3
  • 14
    • 66949162912 scopus 로고    scopus 로고
    • Number needed to treat and number needed to harm are not the best way to report and assess the results of randomised clinical trials
    • Hutton JL. Number needed to treat and number needed to harm are not the best way to report and assess the results of randomised clinical trials. Br J Haematol 2009;146:27-30
    • (2009) Br J Haematol , vol.146 , pp. 27-30
    • Hutton, J.L.1
  • 16
    • 0033825852 scopus 로고    scopus 로고
    • Choice of effect measure for epidemiological data
    • Walter SD. Choice of effect measure for epidemiological data. J Clin Epidemiol 2000;53:931-9
    • (2000) J Clin Epidemiol , vol.53 , pp. 931-9
    • Walter, S.D.1
  • 17
    • 77950189829 scopus 로고    scopus 로고
    • CONSORT 2010 statement: Updated guidelines for reporting parallel group randomised trials
    • Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ 2010;340:c332
    • (2010) BMJ , vol.340
    • Schulz, K.F.1    Altman, D.G.2    Moher, D.3
  • 18
    • 0242318334 scopus 로고    scopus 로고
    • Biomarkers of vascular disease linking inflammation to endothelial activation part II
    • DOI 10.1161/01.CIR.0000089093.75585.98
    • Szmitko PE, Wang CH, Weisel RD, et al. Biomarkers of vascular disease linking inflammation to endothelial activation: part II. Circulation 2003;108:2041-8 (Pubitemid 37337575)
    • (2003) Circulation , vol.108 , Issue.17 , pp. 2041-2048
    • Szmitko, P.E.1    Wang, C.-H.2    Weisel, R.D.3    Jeffries, G.A.4    Anderson, T.J.5    Verma, S.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.